Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
60S ribosomal protein L10a (RPL10A) is a highly conserved structural protein that forms part of the large (60S) subunit of the eukaryotic ribosome, primarily responsible for catalyzing protein synthesis in the cytoplasm[1][3][5][7]. It is a member of the L1P family of ribosomal proteins[1][3][5]. Its gene expression can be modulated by specific drugs (e.g., cyclosporin-A) and during development[1][3]. RPL10A is not considered a classic therapeutic target (such as a receptor, enzyme, transporter, etc.) but is essential for translation and cell viability. Disruption of its function causes defects in cell and organismal development, including anemia due to effects on erythropoiesis in animal models[2], but at present, no approved drugs specifically target RPL10A and there is no known clinical use as a biomarker or therapeutic target in humans. The Ensembl gene ENSG00000213172 does not correspond to RPL10A in humans; the correct Ensembl ID is ENSG00000198755[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 60S ribosomal protein L10a (RPL10A).